{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:52:09Z","timestamp":1770227529941,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Idiopathic Generalized Epilepsy (IGE) patients may not achieve optimal seizure control with monotherapy. Our goal was to evaluate the efficacy of combination therapy in a retrospective series of IGE patients receiving different antiseizure medication (ASM) regimens. We retrospectively identified all patients with adolescence onset IGE with typical clinical and EEG features from a single epilepsy specialist clinic from 2009 to 2020. We evaluated long-term seizure control, for VPA, LEV, LTG mono and combination therapy. We studied 59 patients. VPA was more commonly used in men (84%) than in women (44%) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). VPA was the initial drug of choice in 39% of patients, followed by LEV (22%) and LTG (14.9%). Thirty-nine patients (66.1%) achieved complete seizure control for at least one year. Fifty patients (84.7)% had partial control, without GTC occurrence, for at least one year. VPA was superior to LTG for complete seizure control (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), but not for minor seizure control or pseudoresistance (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Combination therapy was superior to LEV and LTG monotherapy for complete control (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), without differences for minor seizures and pseudoresistance outcomes (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Combination therapy not including VPA was also non-inferior to VPA monotherapy in all settings. Combination therapy was superior to LTG and LEV monotherapy in IGE, and may be equally effective including or not VPA. Combination therapy including LTG, LEV, and\/or VPA is an effective treatment option after monotherapy failure with one of these ASM in IGE. Dual therapy with LEV\u2013LTG should be considered in monotheraphy failure, to avoid fetal effects of in utero VPA exposure.<\/jats:p>","DOI":"10.1038\/s41598-022-16718-x","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T16:09:59Z","timestamp":1658246999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Seizure control in mono- and combination therapy in a cohort of patients with Idiopathic Generalized Epilepsy"],"prefix":"10.1038","volume":"12","author":[{"given":"Leonardo Zumerkorn","family":"Pipek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique Zumerkorn","family":"Pipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Henrique Martins","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"16718_CR1","unstructured":"McWilliam, M. & Al Khalili, Y. Idiopathic Generalized Epilepsy. in StatPearls (StatPearls Publishing, 2022)."},{"issue":"Suppl 9","key":"16718_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","volume":"46","author":"P Jallon","year":"2005","unstructured":"Jallon, P. & Latour, P. Epidemiology of idiopathic generalized epilepsies. Epilepsia 46(Suppl 9), 10\u201314 (2005).","journal-title":"Epilepsia"},{"key":"16718_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","volume":"119","author":"A Chowdhury","year":"2016","unstructured":"Chowdhury, A. & Brodie, M. J. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Epilepsy Res. 119, 62\u201366 (2016).","journal-title":"Epilepsy Res."},{"key":"16718_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","volume":"6","author":"E Perucca","year":"2007","unstructured":"Perucca, E., French, J. & Bialer, M. Development of new antiepileptic drugs: Challenges, incentives, and recent advances. Lancet Neurol. 6, 793\u2013804 (2007).","journal-title":"Lancet Neurol."},{"key":"16718_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","volume":"85","author":"WE Rosenfeld","year":"2009","unstructured":"Rosenfeld, W. E., Benbadis, S., Edrich, P., Tassinari, C. A. & Hirsch, E. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res. 85, 72\u201380 (2009).","journal-title":"Epilepsy Res."},{"key":"16718_CR6","doi-asserted-by":"publisher","first-page":"108633","DOI":"10.1016\/j.yebeh.2022.108633","volume":"130","author":"J Gesche","year":"2022","unstructured":"Gesche, J., Cornwall, C. D., Delcomyn, L., Rubboli, G. & Beier, C. P. Pseudoresistance in idiopathic\/genetic generalized epilepsies\u2014Definitions, risk factors, and outcome. Epilepsy Behav. 130, 108633 (2022).","journal-title":"Epilepsy Behav."},{"key":"16718_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1600-0404.1985.tb00900.x","volume":"72","author":"D Janz","year":"1985","unstructured":"Janz, D. Epilepsy with impulsive petit mal (Juvenile Myoclonic Epilepsy). Acta Neurol. Scand. 72, 449\u2013459 (1985).","journal-title":"Acta Neurol. Scand."},{"key":"16718_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/seiz.2001.0522","volume":"10","author":"AK Dhanuka","year":"2001","unstructured":"Dhanuka, A. K., Jain, B. K., Daljit, S. & Maheshwari, D. Juvenile myoclonic epilepsy: A clinical and sleep EEG study. Seizure 10, 374\u2013378 (2001).","journal-title":"Seizure"},{"key":"16718_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1059-1311(98)90007-3","volume":"7","author":"JMK Murthy","year":"1998","unstructured":"Murthy, J. M. K., Mohan Rao, C. & Meena, A. K. Clinical observations of juvenile myoclonic epilepsy in 131 patients: A study in South India. Seizure 7, 43\u201347 (1998).","journal-title":"Seizure"},{"key":"16718_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1528-1157.1994.tb02432.x","volume":"35","author":"CP Panayiotopoulos","year":"1994","unstructured":"Panayiotopoulos, C. P., Obeid, T. & Tahan, A. R. Juvenile myoclonic epilepsy: A 5-year prospective study. Epilepsia 35, 285\u2013296 (1994).","journal-title":"Epilepsia"},{"key":"16718_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/jnnp.55.6.497","volume":"55","author":"RA Grunewald","year":"1992","unstructured":"Grunewald, R. A., Chroni, E. & Panayiotopoulos, C. P. Delayed diagnosis of juvenile myoclonic epilepsy. J. Neurol. Neurosurg. Psychiatry 55, 497\u2013499 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"16718_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/1059-1311(92)90039-4","volume":"1","author":"MP Canevini","year":"1992","unstructured":"Canevini, M. P. et al. Juvenile myoclonic epilepsy of Janz: Clinical observations in 60 patients. Seizure 1, 291\u2013298 (1992).","journal-title":"Seizure"},{"key":"16718_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1528-1157.1984.tb04163.x","volume":"25","author":"J Asconap\u00e9","year":"1984","unstructured":"Asconap\u00e9, J. & Penry, J. K. Some clinical and EEG aspects of benign juvenile myoclonic epilepsy. Epilepsia 25, 108\u2013114 (1984).","journal-title":"Epilepsia"},{"key":"16718_CR14","first-page":"1","volume":"3","author":"AN Scand","year":"1998","unstructured":"Scand, A. N., Jain, S., Padma, M. V., Puri, A. & Maheshwari, M. C. Juvenile myoclonic epilepsy: Disease expression among Indian families. Acta neurologica Scandinavica. 3, 1\u20137 (1998).","journal-title":"Acta neurologica Scandinavica"},{"key":"16718_CR15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1212\/01.wnl.0000187118.19221.e4","volume":"65","author":"V Biton","year":"2005","unstructured":"Biton, V. et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65, 1737\u20131743 (2005).","journal-title":"Neurology"},{"key":"16718_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.seizure.2014.03.017","volume":"23","author":"S Jayalakshmi","year":"2014","unstructured":"Jayalakshmi, S. et al. Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy. Seizure 23, 527\u2013532 (2014).","journal-title":"Seizure"},{"key":"16718_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1517\/13543784.15.6.637","volume":"15","author":"M Bialer","year":"2006","unstructured":"Bialer, M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin. Investig. Drugs 15, 637\u2013647 (2006).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"16718_CR18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson, A. G. et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial. Lancet 369, 1016\u20131026 (2007).","journal-title":"Lancet"},{"key":"16718_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17236","author":"E Hirsch","year":"2022","unstructured":"Hirsch, E. et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on nosology and definitions. Epilepsia https:\/\/doi.org\/10.1111\/epi.17236 (2022).","journal-title":"Epilepsia"},{"key":"16718_CR20","doi-asserted-by":"publisher","first-page":"106408","DOI":"10.1016\/j.eplepsyres.2020.106408","volume":"166","author":"R Li","year":"2020","unstructured":"Li, R. et al. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world. Epilepsy Res. 166, 106408 (2020).","journal-title":"Epilepsy Res."},{"key":"16718_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","volume":"83","author":"F Rosenow","year":"2012","unstructured":"Rosenow, F. et al. The LaLiMo trial: Lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy\u2014An open-label, prospective, randomised controlled multicenter study. J. Neurol. Neurosurg. Psychiatry 83, 1093\u20131098 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"16718_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/epi4.12349","volume":"4","author":"K Silvennoinen","year":"2019","unstructured":"Silvennoinen, K. et al. Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open 4, 420\u2013430 (2019).","journal-title":"Epilepsia Open"},{"key":"16718_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.seizure.2021.08.019","volume":"92","author":"N Baheti","year":"2021","unstructured":"Baheti, N. et al. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road. Seizure 92, 112\u2013117 (2021).","journal-title":"Seizure"},{"key":"16718_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14737175.2021.1931126","volume":"21","author":"M Ascoli","year":"2021","unstructured":"Ascoli, M. et al. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy. Expert Rev. Neurother. 21, 1265\u20131273 (2021).","journal-title":"Expert Rev. Neurother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16718-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16718-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:48:33Z","timestamp":1669351713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16718-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16718"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16718-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12350"}}